{"product_id":"antibodysystem-kdg01801","title":"Tarextumab ELISA Kit","description":"\u003cp\u003e\u003cstrong\u003eCatalog No.\u003c\/strong\u003e: KDG01801\u003c\/p\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003eCatalog No.\u003c\/th\u003e\n\u003ctd\u003eKDG01801\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct name\u003c\/th\u003e\n\u003ctd\u003eTarextumab ELISA Kit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003ctd\u003e96 T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStability and Storage\u003c\/th\u003e\n\u003ctd\u003eThe stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eDetection method\u003c\/th\u003e\n\u003ctd\u003eColorimetric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePrecision\u003c\/th\u003e\n\u003ctd\u003eCV\u0026lt;20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSample type\u003c\/th\u003e\n\u003ctd\u003ePlasma, Serum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAssay type\u003c\/th\u003e\n\u003ctd\u003eQuantitative\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSensitivity\u003c\/th\u003e\n\u003ctd\u003e0.156 μg\/ml\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eRange\u003c\/th\u003e\n\u003ctd\u003e0.31-5 μg\/mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eRecovery\u003c\/th\u003e\n\u003ctd\u003e80-120%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eBackground\u003c\/th\u003e\n\u003ctd\u003eTarextumab, is a fully human mAb that inhibits ligand-dependent signaling through both Notch2 and Notch3. Tarextumab was tested in a range of xenograft models and found to be active in breast, ovarian, lung, and pancreatic tumors. Administration of tarextumab delayed tumor recurrence after chemotherapeutic treatment and reduced tumor-initiating cell frequency, particularly in combination with chemotherapy. Mechanism of action studies indicated that tarextumab blocked Notch signaling in both tumor and stromal cells and induced differentiation of tumor cells. In the stromal cells, tarextumab inhibited gene expression required for the function of pericytes, vascular support cells essential for tumor angiogenesis.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlternative Names\u003c\/th\u003e\n\u003ctd\u003eOMP-59R5, CAS: 1359940-55-8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003e2-8 ℃\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eNote\u003c\/th\u003e\n\u003ctd\u003eFor Research Use Only.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"AntibodySystem","offers":[{"title":"96 T","offer_id":52602778321120,"sku":"KDG01801","price":1400.0,"currency_code":"KRW","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0601\/9330\/8896\/files\/AntibodySystem_e38f1b9a-cfa9-425f-9358-d55c64d0fc76.png?v=1778468500","url":"https:\/\/rndmate.com\/products\/antibodysystem-kdg01801","provider":"알앤디메이트","version":"1.0","type":"link"}